Literature DB >> 25561485

Making a medicine out of MDMA.

Ben Sessa1, David Nutt1.   

Abstract

From its first use 3,4,-methylenedioxymethamphetamine (MDMA) has been recognised as a drug with therapeutic potential. Research on its clinical utility stopped when it entered the recreational drug scene but has slowly resurrected in the past decade. Currently there is enough evidence for MDMA to be removed from its Schedule 1 status of 'no medical use' and moved into Schedule 2 (alongside other misused but useful medicines such as heroin and amphetamine). Such a regulatory move would liberate its use as a medicine for patients experiencing severe mental illnesses such as treatment-resistant post-traumatic stress disorder. Royal College of Psychiatrists.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25561485     DOI: 10.1192/bjp.bp.114.152751

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  7 in total

Review 1.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

2.  Motor delays in MDMA (ecstasy) exposed infants persist to 2 years.

Authors:  Lynn T Singer; Derek G Moore; Meeyoung O Min; Julia Goodwin; John J D Turner; Sarah Fulton; Andrew C Parrott
Journal:  Neurotoxicol Teratol       Date:  2016-01-21       Impact factor: 3.763

3.  The role of substance use, smoking, and inflammation in risk for suicidal behavior.

Authors:  He Benny Chang; Sara Munroe; Katarina Gray; Giovanna Porta; Antoine Douaihy; Anna Marsland; David Brent; Nadine M Melhem
Journal:  J Affect Disord       Date:  2018-09-07       Impact factor: 4.839

Review 4.  Tapping onto the Potential of Smartphone Applications for Psycho-Education and Early Intervention in Addictions.

Authors:  Melvyn W B Zhang; Roger C M Ho
Journal:  Front Psychiatry       Date:  2016-03-17       Impact factor: 4.157

Review 5.  MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD: what it is and what it isn't.

Authors:  Louise Morgan
Journal:  Ann Gen Psychiatry       Date:  2020-05-12       Impact factor: 3.455

6.  Psychedelic drugs-a new era in
psychiatry?
.

Authors:  David Nutt
Journal:  Dialogues Clin Neurosci       Date:  2019       Impact factor: 5.986

Review 7.  MDMA and memory, addiction, and depression: dose-effect analysis.

Authors:  Madeline M Pantoni; Jinah L Kim; Kaitlin R Van Alstyne; Stephan G Anagnostaras
Journal:  Psychopharmacology (Berl)       Date:  2022-02-18       Impact factor: 4.415

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.